Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Trial Profile

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jan 2015

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Focus Expanded access; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 02 Sep 2014 Status changed to completed as reported by ClinicalTrials.gov record.
    • 16 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top